KRAS and neoplasm: Indeed, treatment of bryostatin-1, a potent activator of PKC, effectively phosphorylated Serine 181 of KRAS, mislocalized an oncogenic mutant KRAS from the PM and promoted apoptosis of the mutant KRAS-dependent tumor cells [81].